Pioglitazone Therapy Targeting Fatigue in Breast Cancer
Status:
Not yet recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
The goal of this project is to evaluate the therapeutic potential of pioglitazone (PIO) to
target underlying mechanisms that promote muscle fatigue in patients with breast cancer. This
represents an off-label use of this compound, both in terms of the patient population and the
clinical phenotype targeted. The central research hypothesis of this study is that daily
pioglitazone will restore transcriptional downregulation of pathways within skeletal that
promote fatigue.